BIOMAKERS, a precision medicine and oncology intelligence company headquartered in San Francisco, today announced the closing of an additional $8 million. The financing marks a key inflection point as the company transitions from building a differentiated global diagnostics and data infrastructure to scaling an AI-native platform – while continuing to expand its comprehensive molecular testing reach across Latin America – designed to accelerate drug and diagnostic development, improve clinical trial execution, and enable precision oncology at global scale.

Truvian Health (“Truvian”), a diagnostics company redefining routine blood testing, today announced U.S. Food and Drug Administration (FDA) clearance for the Complete Blood Count (CBC) on its TruVerus™ multi‑modal blood testing system (K251249).

In November 2025, China's National Health Commission and four other authorities have called for the broader application of artificial intelligence (AI) in the country's health sector over the coming years. ..

Roche's (ROG.S), opens new tab Genentech said on Tuesday it will more than double its initial investment in a biomanufacturing facility in North Carolina to about $2 billion, as the companies look to further boost their $50 billion investment in the U.S.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck’s oncology portfolio using the Guardant Infinity™ Smart platform.

2.1.1 Brand Research and Analysis on the Use of Blood Coagulation Analyzers in Different Medical Institutions According to the results of the basic research (Fig. 2), different medical institutions have ..

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a state-of-the-art multi-modality breast biopsy system designed to provide clinicians with flexibility across breast imaging modalities in the diagnosis of breast disease.

Autobio Diagnostics’ hs-cTnT Assay Recognized by IFCC as Global Performance Benchmark Autobio Diagnostics recently announced that its high-sensitivity cardiac troponin T (hs-cTnT) assay (magnetic partic..

BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced a collaboration with Epic, the nation's most widely used comprehensive electronic health record (EHR). The agreement, signed in December 2025, will integrate BillionToOne's prenatal and oncology testing portfolio with Epic's Aura diagnostics suite.

BGI Genomics (300676.SZ), opens new tab and Roche Diagnostics (ROG.S), opens new tab have rolled out tests for Alzheimer's disease in China, the companies said, in an effort to expand access to easier-to-use diagnosis and monitoring choices for patients with the brain-wasting condition.

Roche Diagnostics’ MTB Nucleic Acid Test Kit and Domestic cobas 5800 Molecular Diagnostic System Receive NMPA Approval Roche Diagnostics China announced that the cobas® MTB Mycobacterium tuberculosi..

Original from: PR Newswire GenomOncology (GO), a leader in precision medicine reporting solutions, today announced a strategic partnership with Oregon Health & Science University's (OHSU) Knight Diag..

Altoida, Inc., a pioneer in AI- and AR-powered digital diagnostics for neurological diseases, today announced a research collaboration with Mindspan, the cognitive care company focused on changing the trajectory of decline for patients with Alzheimer's disease and related conditions. Together, the companies will conduct an investigational pilot study evaluating the clinical, operational, and potential economic impacts of integrating Altoida’s rapid, AI/AR-powered digital NeuroMarker platform into Mindspan’s innovative cognitive care delivery model.

Synthego, a recognized leader in CRISPR solutions, announces its formal entry into the molecular and clinical diagnostic reagents sector. Building upon its reputation for rigorous quality, custom manufacturing, and innovation, Synthego's significant expansion of its product portfolio empowers researchers, clinicians, and diagnostic laboratories with high-quality, reliable reagents designed to accelerate the development and deployment of cutting-edge diagnostic tests.

Sedia Biosciences Corporation, a leading developer of innovative diagnostic tests for infectious diseases, today announced that its Asanté® HIV-1/2 Oral Fluid Test has received Pre-Qualification (PQ) status from the World Health Organization (WHO). This significant achievement enables global procurement and widespread use of this rapid diagnostic test.